HEOR News Roundup

Tuesday, November 19, 2019 | Issue 478

Subscribe Contact Advertise HEOR & RWE Marketplace

Sponsored by

NMSS Slams Biogen Over
Price of New Drug

The price of Biogen’s new drug, Vumerity, has been heavily criticized by the National Multiple Sclerosis Society, STAT reports.

Read More

ISPOR Extends Comment Deadline for Draft White Paper


Letters Criticize ICER’s Methods


Amazon, Deloitte Partner to Bolster AWS Data Exchange


Gottlieb Forecasts Accelerated Use of RWE in Drug Approvals

 

   Conference

 

Pharmacy Benefit Management Compliance Congress

November 20-21 | Scottsdale, Arizona

 

   Webinar

 

How to find and recruit the right patients for your Cell and Gene Therapy

November 20

 
 
Syndicated Reports
   
Global Health Economics & Outcomes Research (HEOR) Services Market Size, Share, Growth, Status and Forecast 2019-2025
 
Global Value-Based Reimbursement Software Market Size, Status and Forecast to 2026
 
White Papers
   
Current Landscape: Value Assessment Frameworks
 
The New Health Economy is Here. Do You Have the Right Knowledge Resources in Place?
 
 
  Economic Modeling, Manager – Associate Director (Remote Position) Assistant/Associate Director – HEOR (Home-Based) Health Economics and Outcomes Researcher Senior Health Economics and Outcomes Researcher  
 
 
 
 

Share this newsletter!